Renaissance Technologies
KYTX icon

Renaissance Technologies’s Kyverna Therapeutics KYTX Stock Holding History

Renaissance Technologies’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Sell
333,899
-33,593
-9% -$298K ﹤0.01% 1745
2026
Q1 		$3.17M Buy
367,492
+189,593
+107% +$1.58M 0.01% 1636
2025
Q4 		$1.67M Buy
177,899
+13,285
+8% +$98.6K ﹤0.01% 1977
2025
Q3 		$988K Buy
164,614
+42,197
+34% +$169K ﹤0.01% 2489
2025
Q2 		$376K Sell
122,417
-2,541
-2% -$6.29K ﹤0.01% 2968
2025
Q1 		$241K Buy
124,958
+80,258
+180% +$237K ﹤0.01% 3009
2024
Q4 		$167K Buy
+44,700
New +$214K ﹤0.01% 3209

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Renaissance Technologies's KYTX Position: Q2 2026 in Review

Renaissance Technologies reduced its Kyverna Therapeutics (KYTX) stake by 9.1% in Q2 2026, selling an estimated $298K and leaving 333,899 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Renaissance Technologies first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.17M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Renaissance Technologies held 333,899 shares of Kyverna Therapeutics worth $2.98M as of Q2 2026.
  • Renaissance Technologies sold 33,593 Kyverna Therapeutics shares in Q2 2026, an estimated $298K.
  • Kyverna Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1745 holding.
  • Renaissance Technologies first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Renaissance Technologies's Kyverna Therapeutics position peaked at $3.17M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.